Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioxytran Inc BIXT

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.


OTCQB:BIXT - Post by User

Post by christopher707on Mar 07, 2024 8:04am
37 Views
Post# 35919932

Bioxytran ($BIXT): Resilient Growth in Pharmaceuticals

Bioxytran ($BIXT): Resilient Growth in PharmaceuticalsWith a market cap of $19.87 million and 165.59 million outstanding shares, Bioxytran ($BIXT) is a force in pharmaceuticals. Averaging a 30-day volume of 62,545 and boasting a 52-week range of $0.071–$1.05, Bioxytran's resilience and growth potential are evident. With 300 million authorised shares and a float of 28,687,245, the company is strategically positioned for groundbreaking medical advancements. 


Access the website  www.bioxytraninc.com
<< Previous
Bullboard Posts
Next >>